| 杨 欣,鲁利群,黄 莉,汪 燕,王 旭,邓国清,赵泽宇.泛福舒胶囊辅助治疗小儿支气管哮喘的临床研究[J].现代生物医学进展英文版,2017,17(10):1949-1952. |
| 泛福舒胶囊辅助治疗小儿支气管哮喘的临床研究 |
| A Clinical Study on Broncho-vaxom Capsules in Adjuvant Therapy of Children with Bronchial Asthma |
| Received:August 30, 2016 Revised:September 23, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.10.040 |
| 中文关键词: 泛福舒胶囊 小儿 支气管哮喘 免疫功能 临床疗效 |
| 英文关键词: Broncho-vaxom Capsules Children Bronchial Asthma Immunologic Function Clinical Effects |
| 基金项目:四川省卫生厅基金项目(130250) |
|
| Hits: 465 |
| Download times: 255 |
| 中文摘要: |
| 摘要 目的：研究泛福舒胶囊辅助治疗小儿支气管哮喘(BA)的临床疗效及安全性。方法：选择2014年10月～2015年9月于成都医学院第一附属医院儿科接受治疗的急性发作期BA患儿88例，依照随机数字表法1:1分为泛福舒组(n=44)与对照组(n=44)。对照组在常规治疗的基础上给予布地奈德气雾剂治疗，泛福舒组在对照组的基础上给予泛福舒胶囊治疗。观察和比较两组治疗前后肺功能指标PEF(呼气峰流速)、FEV1，CD3+、CD4+、CD8+、CD4+/CD8+T淋巴细胞水平，血清IL-4、IL-5、IL-12、IFN-γ水平以及治疗期间不良反应的发生情况和临床疗效；结果：治疗后，两组PEF、FEV1、CD3+、CD4+、CD4+/CD8+、IL-12、IFN-γ水平均高于治疗前，CD8+、IL-4、IL-5水平均低于治疗前，且泛福舒组PEF、FEV1、CD3+、CD4+、CD4+/CD8+、IL-12、IFN-γ水平均高于对照组，CD8+、IL-4、IL-5水平均低于对照组，差异均有统计学意义(p＜0.05)。泛福舒组总有效率(93.18%)显著高于对照组(75.00%)，组间比较有统计学差异(p＜0.05)。泛福舒组不良反应发生率(4.55%)与对照组不良反应发生率(0%)无统计学差异。结论：泛福舒胶囊辅助治疗可更有效提高BA患儿的临床疗效，改善其肺功能，增强其免疫防御能力，且安全性较高，值得应用于临床。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical effects and safety of Broncho-vaxom capsules in the adjuvant therapy of bronchial asthma (BA) in children. Methods: 88 cases of children with BA in acute-outbreak period who were treated in the department of Pediatrics from October, 2014 to September, 2015 in the First Affiliated Hospital of Chengdu Medical College were selected. Based on the random number table method, they were divided into the Broncho-vaxom group (n = 44) and control group (n = 44) in a 1:1 ratio. There was no statistical difference in the baseline data between the two groups (p<0.05). Besides conventional treatment, Budesonide Aerosol treatment was applied in the control group. The Broncho-vaxom group was treated with Broncho-vaxom capsules on the basis of treatment of control group. Lung function index PEF (peak expiratory flow), FEV1, levels of T lymphocytes including CD3+, CD4+, CD8+ and CD4+/CD8, levels of IL-4, IL-5, IL-12 and IFN-γ in serum, occurrence of adverse reactions during treatment and clinical effects of the two groups were observed and compared before and after treatment. Results: After treatment, the levels of PEF, FEV1, CD3+, CD4+, CD4+/CD8 , IL-12 and IFN-γ in both groups were higher than those before treatment, and the levels of PEF, FEV1, CD3+, CD4+,CD4+/CD8 , IL-12 and IFN-γ of Broncho-vaxom group were higher than those of the control group. The levels of CD8+, IL-4 and IL-5 were lower than those of the control group(p<0.05). The total effective rate of Broncho-vaxom group (93.18%) was significantly higher than that of the control group (75%)(p<0.05). No statistical difference was found in the incidence of adverse reactions between the Broncho-vaxom group (4.55%) and control group (0%). Conclusion: Broncho-vaxom adjuvant therapy could more significantly enhance the clinical effects of BA in children, improve their lung function, strengthen their immune defence and had high safety, so it was worthy of clinical application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
